𝐎𝐮𝐫 𝐯𝐞𝐫𝐲 𝐨𝐰𝐧 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐠𝐨𝐞𝐬 𝐨𝐧 𝐡𝐮𝐦𝐚𝐧 𝐭𝐫𝐢𝐚𝐥𝐬...

𝐎𝐮𝐫 𝐯𝐞𝐫𝐲 𝐨𝐰𝐧 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐠𝐨𝐞𝐬 𝐨𝐧 𝐡𝐮𝐦𝐚𝐧 𝐭𝐫𝐢𝐚𝐥𝐬...

The COVID-19 vaccine candidate - LUNAR-COV19 - has been approved to proceed by the Singapore Health Sciences Authority. 👍👍

Arcturus and Duke-NUS partnered to develop it using Arcturus’ STARR™ technology and a unique platform developed at Duke-NUS allowing rapid screening of vaccines for potential effectiveness and safety.

Arcturus and Duke-NUS will initiate human dosing of LUNAR-COV19 as soon as possible.

The healthy volunteer study will evaluate several dose levels of LUNAR-COV19 in up to 108 adults, including older adults.

Follow-up will be conducted to evaluate safety, tolerability and the extent and duration of the humoral and cellular immune response.

Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases Program at Duke-NUS, said, “Preclinical studies on LUNAR-COV19 have shown very promising findings, including the possibility that a single dose of this vaccine may be sufficient to trigger robust and durable immune responses against SARS-CoV-2. We are very eager to start the first-in-human clinical trial here in Singapore and advance LUNAR-COV19 on its journey to becoming a potential commercial vaccine.”